Company NANO MRNA Co.,Ltd.

Equities

4571

JP3651120002

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per region

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-25 am EDT			5-day change	1st Jan Change
177 ^JPY	-0.56%		+0.57%	-6.84%

2023	NANO MRNA, Kao Tie Up to Develop mRNA Therapies for Allergic Diseases	MT
2023	NANO MRNA Co., Ltd. and Kao Corporation Agree a Comprehensive Collaborative Research for mRNA Drug Discovery	CI

Nano Mrna Co Ltd, formerly NanoCarrier Co Ltd, is mainly engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company develops businesses using the research and development of messenger ribonucleic acid (mRNA) medicine. The products under development are specialized in mRNA medicines. mRNA medicine is a medicine that prevents or treats diseases by administering artificially produced mRNA to the body and allowing the body to discover the protein encoded by the mRNA. Its pipeline includes RUNX1, the mRNA drug pipeline, non-mRNA drug pipeline, Comrex otological liquid 1.5%, NC-6100, TUG1, and others.

Number of employees: 17

JPY in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	264	100.0 %	202	100.0 %	-23.42%

JPY in Million	2022	Weight	2023	Weight	Delta
Japan 75.9 %	164	62.0 %	153	75.9 %	-6.29%
Taiwan 24.1 %	100	38.0 %	49	24.1 %	-51.38%

Managers	Title	Age	Since
Shiro Akinaga CEO	Chief Executive Officer	67	20-05-31
Koji Fujimoto DFI	Director of Finance/CFO	51	02-10-31
Tetsuhito Matsuyama AUD	Comptroller/Controller/Auditor	61	14-11-30

Members of the board	Title	Age	Since
Satoru Iino BRD	Director/Board Member	58	12-02-29
Kazunori Kataoka FOU	Founder	73	96-06-13
Teruo Okano FOU	Founder	75	96-06-13
Tetsuhito Matsuyama AUD	Comptroller/Controller/Auditor	61	14-11-30
Atsushi Matsumura CHM	Chairman	62	12-02-29
Shiro Akinaga CEO	Chief Executive Officer	67	20-05-31
Yuki Hasegawa BRD	Director/Board Member	46	21-05-31
Koji Fujimoto DFI	Director of Finance/CFO	51	02-10-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	70,393,158	65,797,230 ( 93.47 %)	11,428 ( 0.0162 %)	93.47 %

Name	Equities	%	Valuation
SHIN-ETSU CHEMICAL CO., LTD. 2.358 %	1,660,000	2.358 %	2 M ¥
Ichiro Nakatomi 1.355 %	954,000	1.355 %	1 M ¥
NORITSU KOKI CO., LTD. 1.065 %	750,000	1.065 %	916 778 ¥
Keiji Kensetsu KK 0.9105 %	640,900	0.9105 %	783 417 ¥
Masatsugu Kimura 0.8666 %	610,000	0.8666 %	745 646 ¥
Whiz Partners, Inc. 0.7103 %	500,000	0.7103 %	611 185 ¥
Kazunori Kataoka 0.4608 %	324,350	0.4608 %	396 476 ¥
Teruo Okano 0.4600 %	323,800	0.4600 %	395 803 ¥
Nanocarrier Restricted Stock Compensation Plan 0.4360 %	306,900	0.4360 %	375 145 ¥
Tetsuhito Matsuyama 0.1242 %	87,400	0.1242 %	106 835 ¥

Name	Equities	%	Valuation
KIDSWELL BIO CORPORATION 2.60%	1,000,000	2.60%	991,110 $
NANO MRNA CO.,LTD. 0.02%	11,400	0.02%	13,935 $

NANO MRNA Co., Ltd.

Atago Green Hills Mori Tower 26F 2-5-1 Atago

105-6212, Tokyo

+81 3 6432 4791

http://www.nanomrna.co.jp

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
NANO MRNA CO.,LTD.	-6.84%	80.79M
VERTEX PHARMACEUTICALS INCORPORATED	-2.12%	104B
REGENERON PHARMACEUTICALS, INC.	+1.73%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.87%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-15.45%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.05%	13.98B
SAREPTA THERAPEUTICS, INC.	+34.81%	11.66B

Bio Therapeutic Drugs